AbbVie Shares Rise 3.1% - Still a Buy?

The pharmaceutical company's stock price jumped after positive analyst reports, but some remain cautious on its long-term outlook.

Mar. 2, 2026 at 11:55pm

Got story updates? Submit your updates here. ›

AbbVie Inc.'s (NYSE:ABBV) share price rose 3.1% during mid-day trading on Friday, reaching as high as $232.27 per share. The stock surge came after several analysts issued reports on the company, with some maintaining a 'buy' rating and others taking a more neutral stance. AbbVie is a global biopharmaceutical company focused on developing therapies for complex and chronic medical conditions across multiple therapeutic areas.

Why it matters

AbbVie's stock performance is closely watched by investors as the company navigates patent expirations on some of its key drugs and seeks to expand its pipeline of new treatments. The mixed analyst views reflect the ongoing uncertainty around AbbVie's long-term growth prospects as it faces increased competition in certain drug categories.

The details

According to the report, AbbVie saw 7.9 million shares traded on Friday, up 9% from the average daily volume. The stock closed at $231.69, up 3.1% from the previous day's close of $224.69. Analysts at firms like UBS Group, Sanford C. Bernstein, and BMO Capital Markets have issued reports on AbbVie in recent weeks, with some maintaining 'buy' ratings and price targets above $250, while others have lowered their price objectives to the $230 range and assigned 'neutral' ratings.

  • AbbVie's 50-day moving average is $224.34 and its 200-day moving average is $223.11.
  • The company is scheduled to pay a quarterly dividend of $1.73 per share on May 15, 2026 to shareholders of record as of April 15, 2026.

The players

AbbVie Inc.

A global, research-driven biopharmaceutical company that was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions.

UBS Group

A global financial services firm that has issued a report on AbbVie, cutting its price target from $240 to $230 and maintaining a 'neutral' rating on the stock.

Sanford C. Bernstein

An investment research and management firm that has reissued a 'market perform' rating on AbbVie shares.

BMO Capital Markets

An investment bank that has reiterated an 'outperform' rating and $258 price target on AbbVie stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

AbbVie's stock surge reflects ongoing investor interest in the company's ability to navigate patent expirations and expand its drug pipeline, but the mixed analyst views suggest there is still uncertainty around the company's long-term growth prospects as it faces increased competition in certain therapeutic areas.